JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting…
Metabolic Disorders
-
-
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.…
-
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral small…
-
FDA targets more online vendors selling unapproved GLP-1RA products
The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like peptide-1 receptor agonist…
-
Egyptian Drug Authority approves Lilly and EVA’s insulin injection
Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection to…
-
Eli Lilly to invest $3bn in Wisconsin facility expansion
Eli Lilly has announced a $3bn investment to expand its newly acquired manufacturing facility in Kenosha County, Wisconsin, US, which…
-
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
Eli Lilly has scored a win in the ongoing competition with Novo Nordisk in the obesity space, as a Phase…
-
Wait for galactosemia therapy goes on after FDA shuns Applied Therapeutics’ govorestat
The US Food and Drug Administration (FDA) has declined to approve Applied Therapeutics’ govorestat for classic galactosemia, prolonging the wait…
-
Eton acquires US rights to neonatal diabetes treatment from AMMTeK
Eton Pharmaceuticals has acquired the US rights to Amglidia, a treatment developed for neonatal diabetes mellitus, from France-based biotechnology company…
-
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology company Ypsomed could include the supply of…
